Related Experiment Video
Updated: Jul 29, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver?
1SocraTec R&D, Feldbergstrasse 59, 61440, Oberursel, Germany. h.h.blume@t-online.de
Abstract:
Current guidelines (CPMP Note for Guidance in Europe and FDA Guidance for Industry in the USA) consider a waiver of bioavailability/bioequivalence studies for immediate release dosage forms of highly soluble, highly permeable drug substances (Class I according to the BCS). In this paper, a waiver of BA/BE studies is being proposed also for Class III compounds (high solubility and low permeability) in fast dissolving products without excipients which may modify gastro-intestinal transit or membrane permeation. This type of drug substance may be an even better candidate for a waiver as, in this case, bioavailability will not so much depend on the formulation characteristics, as on drug substance properties (e.g. permeability).
More Related Videos
11:28A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
Drug Classes and Categories
Hepatic Drug Clearance: Role of Transporters
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Bioequivalence studies: Biowaivers
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Product Performance: In Vitro–In Vivo Correlation